US 12,258,419 B2
Anti-FXI/FXIa antibody and use thereof
Haijun Tian, Cranbury, NJ (US); Dengnian Liu, Chengdu (CN); Sujun Deng, Cranbury, NJ (US); Marc Peter Ciucci, Cranbury, NJ (US); Cheng Wang, Chengdu (CN); Yong Zheng, Chengdu (CN); Liang Xiao, Chengdu (CN); Tongtong Xue, Chengdu (CN); and Jingyi Wang, Chengdu (CN)
Assigned to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu (CN); and Klus Pharma Inc., Cranbury, NJ (US)
Appl. No. 17/310,957
Filed by SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., Chengdu (CN); and KLUS PHARMA INC., Cranbury, NJ (US)
PCT Filed Apr. 6, 2020, PCT No. PCT/CN2020/083413
§ 371(c)(1), (2) Date Sep. 1, 2021,
PCT Pub. No. WO2020/211674, PCT Pub. Date Oct. 22, 2020.
Claims priority of application No. 201910303627.7 (CN), filed on Apr. 16, 2019.
Prior Publication US 2022/0162338 A1, May 26, 2022
Int. Cl. C07K 16/36 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); G01N 33/86 (2006.01)
CPC C07K 16/36 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); G01N 33/86 (2013.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/96452 (2013.01)] 27 Claims
 
1. An antibody or antigen-binding fragment thereof capable of specifically binding to FXI and/or FXIa, wherein the antibody or antigen-binding fragment thereof comprises:
(a) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 3, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 4, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 5; and
a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 6, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 7, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 8; wherein the six CDRs are defined by the IMGT numbering system;
(b) a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 33, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 34, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 35; and
a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 36, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 37, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 38; wherein the six CDRs are defined by the IMGT numbering system;
(c) a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, a CDR-H2 comprising the amino acid sequence of any one of SEQ ID NOs: 45, 46, and 10, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11; and a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14; wherein the six CDRs are defined by the AbM numbering system; or
(d) a VH comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 39, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 40 or 47, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 41; and a VL comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 42, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 43, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 44; wherein the six CDRs are defined by the AbM numbering system.